NCT00223678 is a Phase 4 clinical trial of Rapamycin in Kidney Transplant, sponsored by Vanderbilt University Medical Center.

Who is sponsoring NCT00223678?

NCT00223678 is sponsored by Vanderbilt University Medical Center.

What drugs are being tested in NCT00223678?

Interventions in NCT00223678: Rapamycin.

What condition does NCT00223678 study?

NCT00223678 studies Kidney Transplant.

Is NCT00223678 still recruiting?

NCT00223678 is currently completed. Last updated 24 May 2017.

Are results published for NCT00223678?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-05-24 · How we verify

NCT00223678

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure

Completed Phase 4 Results posted Last updated 24 May 2017

What this trial tests

Phase 4 trial testing Rapamycin in Kidney Transplant in 20 participants. Completed in 1 October 2009.

Timeline

1 June 2000

Primary endpoint
1 October 2009

1 October 2009

Quick facts

Lead sponsor	Vanderbilt University Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 June 2000
Primary completion	1 October 2009
Estimated completion	1 October 2009
Sites	1 location across United States

Drugs / interventions tested

Rapamycin — full drug profile →

Conditions studied

Kidney Transplant — all drugs for Kidney Transplant →

Sponsor

Vanderbilt University Medical Center

Who can join

12 and older, any sex, with Kidney Transplant. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Graft Survival
Time frame: 3 years

Sponsor's own description

A study to determine the effect on renal function in renal transplant patients with biopsy proven Chronic allograft nephropathy (CAN) nephropathy who are switched from a Calcinerin inhibitor (CI) triple drug regimen to a Rapamycin based triple drug regimen or maintained on their CI protocol

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Rapamycin

Trials testing the same drug.

NCT06743503 — UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies · Phase 1 · recruiting
NCT06257420 — Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions · enrolling by invitation
NCT06550271 — The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals · completed
NCT05342519 — Daily Topical Rapamycin for Vitiligo · Phase 2 · active not recruiting
NCT04736589 — Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway · Phase 3 · not yet recruiting

Other recruiting trials for Kidney Transplant

Currently open trials in the same condition.

NCT07532382 — Personalized Stories for Pediatric Kidney Recipients · recruiting
NCT07348458 — Kidney Protective Jacket · NA · recruiting
NCT07333495 — A Mixed Cohort, Multicentre Exploratory Study of Non-invasive Quantitative Assessment of Renal Graft Function With Non-c · recruiting
NCT06919003 — Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE · Phase 2 · recruiting
NCT07205692 — Multimorbidity and Cardiovascular Risk Factors After Renal Transplant · recruiting

Other Vanderbilt University Medical Center trials

Trials by the same sponsor.

NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults · not yet recruiting
NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · NA · not yet recruiting
NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis · Phase 4 · not yet recruiting
NCT07431541 — Topical Carboxytherapy Paste Following Microneedling · Phase 1, PHASE2 · not yet recruiting
NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00223678 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 24 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00223678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing